Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Wednesday 17 November, 2010

Lipoxen PLC

Walbrook PR appointed by Lipo

RNS Number : 2963W
Lipoxen PLC
17 November 2010
 



 

Walbrook PR appointed by Lipoxen plc as financial PR and IR advisor

 

 

Lipoxen (AIM: LPX.L), ('Lipoxen' or 'the Company') a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, is pleased to announce the appointment of Walbrook PR Ltd as its financial PR and IR advisor.

 

For further information, please contact:

Enquiries

Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

 

 

 

Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång

 

 

 

Walbrook PR Ltd

+44 (0)20 7933 8780

Paul McManus (Media Relations)

paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Relations)

paul.cornelius@walbrookir.com

 

 

 

About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:

 

1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA

 

Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 

 

Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for blood coagulation drugs.

 

The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a £1.2 million placing in April 2010 which was led by the Company's management team.

 

Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRGMMMMNVFGGZM